Asterias: Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 12a Clinical Trial

Asterias Biotherapeutics NYSEAST a biotechnology company dedicated to developing cellbased therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer today provided topline 12 month data from th...